GlobeNewswire Inc.··DelveinsightPARP Inhibitor Pipeline Surges: 25+ Pharma Giants Race to Expand Cancer Drug Arsenal
Over 25 pharma companies develop 30+ PARP inhibitors in trials, with AstraZeneca and Gilead leading expansion into multiple cancer indications including glioblastoma and prostate cancer.
AZNGILDALLRclinical trialscancer treatment